ARTICLE | Company News
SHR acquires ABT dermatitis compound
November 6, 2001 8:00 AM UTC
Schering (SHR) acquired the worldwide rights to develop and market ABT-281, a topical non-steroidal immunosuppressant from Abbott (ABT), for atopic dermatitis and other dermatological diseases. ...